EVAX Evaxion Biotech A/S
Healthcare$4.11+0.74%ClosedMarket Cap: $26.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.00
P/S
3.42
EV/EBITDA
-0.90
DCF Value
$37.49
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-122.2%
Net Margin
-129.8%
ROE
-77.9%
ROA
-34.4%
ROIC
-34.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-3.8M | $-3.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-4.1M | $-5.9M | $— | — |
| FY null | $7.5M | 100.0% | $-9.2M | $-7.7M | $— | — |
| Q3 null | $7.5M | 100.0% | $3.0M | $4.6M | $— | — |
| Q2 null | $37.0K | 100.0% | $-4.3M | $-4.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.9M | $-1.6M | $— | — |
| Q4 null | $122.0K | 100.0% | $-4.0M | $-3.6M | $— | — |
| FY null | $3.3M | 100.0% | $-14.7M | $-10.6M | $— | — |
| Q3 null | $3.0M | 100.0% | $-1.7M | $-1.9M | $— | — |
| Q2 null | $154.0K | 100.0% | $-4.6M | $-6.2M | $— | — |
| Q1 null | $51.0K | 100.0% | $-4.4M | $1.2M | $— | — |
| Q4 2023 | $73.0K | 100.0% | $-4.4M | $-4.5M | $-6.60 | — |